IRCT20171105037262N4RecruitingPhase 3
Evaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19
Bagheiat-allah University of Medical Sciences0 sites100 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- no limit to no limit (—)
- Sex
- All
Inclusion Criteria
- •Having COVID-19
- •Respiratory distress with over 30 breaths per minute
- •O2 saturation less than 93% at rest
- •PaO2/Fio2 less than 300 mmHg
- •HRCT indicating COVID-19
- •positive PCR test result
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Not yet recruiting
Phase 2
The effect of Adalimumab in the treatment of patients with chronic schizophreniaSchizophrenia.SchizophreniaIRCT20090117001556N126Tehran University of Medical Sciences50
Completed
Not Applicable
Trough level related side-effects of adalimumab therapy in patients with inflammatory bowel disease in clinical and biochemical remission, a cross-sectional cohort studyinflammatory bowel disease10017969NL-OMON40963Academisch Medisch Centrum40
Completed
Not Applicable
Prospective study on the effects of adalimumab treatment in patients with rheumatoid arthritisMusculoskeletal DiseasesArthropathiesRheumatoid arthritisISRCTN68762628Academic Medical Center (AMC) (The Netherlands)50
Completed
Phase 3
Therapeutic Effects of Adalimumab in Patients with Resistant PsoriasisIRCT20120524009844N8Tabriz University of Medical Sciences60
Completed
Not Applicable
Clinical Effectiveness of Adalimumab (Exemptiaâ?¢) in patients suffering from symptomatic Ankylosing Spondylitis (AS) under supervised standard rheumatology careCTRI/2018/02/012018CENTER FOR RHEUMATIC DISEASES50